Compare SCOR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | MXCT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 93.0M |
| IPO Year | 2007 | 2021 |
| Metric | SCOR | MXCT |
|---|---|---|
| Price | $6.45 | $1.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 9.7K | ★ 973.4K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,549,000.00 | $33,026,000.00 |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.30 | $18.50 |
| P/E Ratio | $1.55 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $0.64 |
| 52 Week High | $10.18 | $2.40 |
| Indicator | SCOR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 61.92 |
| Support Level | $6.22 | $0.77 |
| Resistance Level | $7.07 | $1.16 |
| Average True Range (ATR) | 0.38 | 0.08 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 20.38 | 66.76 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.